Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model
Virginie Follin-Arbelet1, Peter O Hofgaard, Harald Hauglin
1Department of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. virginie.follin-arbelet@medisin.uio.no
Background:
Multiple myeloma is an incurable disease requiring the development of effective therapies which can be used clinically. We have elucidated the potential for manipulating the cAMP signaling pathway as a target for inhibiting the growth of multiple myeloma cells.
Methods:
As a model system, we primarily used the murine multiple myeloma cell line MOPC315 which can be grown both in vivo and in vitro. Human multiple myeloma cell lines U266, INA-6 and the B-cell precursor acute lymphoblastic leukemia cell line Reh were used only for in vitro studies. Cell death was assessed by flow cytometry and western blot analysis after treatment with cAMP elevating agents (forskolin, prostaglandin E2 and rolipram) and cAMP analogs. We followed tumor growth in vivo after forskolin treatment by imaging DsRed-labelled MOPC315 cells transplanted subcutaneously in BALB/c nude mice.
Results:
In contrast to the effect on Reh cells, 50 μM forskolin more than tripled the death of MOPC315 cells after 24 h in vitro. Forskolin induced cell death to a similar extent in the human myeloma cell lines U266 and INA-6. cAMP-mediated cell death had all the typical hallmarks of apoptosis, including changes in the mitochondrial membrane potential and cleavage of caspase 3, caspase 9 and PARP. Forskolin also inhibited the growth of multiple myeloma cells in a mouse model in vivo.
Conclusions:
Elevation of intracellular levels of cAMP kills multiple myeloma cells in vitro and inhibits development of multiple myeloma in vivo. This strongly suggests that compounds activating the cAMP signaling pathway may be useful in the field of multiple myeloma.
Insights
Elevating cyclic adenosine monophosphate (cAMP) levels effectively kills multiple myeloma cells in vitro and inhibits tumor growth in vivo. This suggests targeting the cAMP pathway offers a promising therapeutic strategy for multiple myeloma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multiple myeloma is an incurable hematologic malignancy.
- There is a clinical need for novel and effective therapeutic strategies.
- The cyclic adenosine monophosphate (cAMP) signaling pathway is explored as a potential therapeutic target.
Purpose of the Study:
- To investigate the potential of manipulating the cAMP signaling pathway to inhibit multiple myeloma cell growth.
- To assess the efficacy of cAMP-elevating agents in preclinical models of multiple myeloma.
Main Methods:
- Murine (MOPC315) and human (U266, INA-6) multiple myeloma cell lines were used for in vitro studies.
- Cell death was analyzed via flow cytometry and western blot after treatment with cAMP-elevating agents (e.g., forskolin).
- In vivo efficacy was evaluated using a murine model with subcutaneous MOPC315 tumors.
Main Results:
- Forskolin significantly increased cell death in multiple myeloma cell lines, but not in control leukemia cells.
- cAMP-mediated cell death exhibited hallmarks of apoptosis, including mitochondrial membrane potential changes and caspase activation.
- Forskolin treatment inhibited multiple myeloma tumor growth in a preclinical mouse model.
Conclusions:
- Elevating intracellular cAMP levels induces apoptosis in multiple myeloma cells.
- Targeting the cAMP signaling pathway demonstrates therapeutic potential for inhibiting multiple myeloma progression.
- Compounds that activate the cAMP pathway may represent a viable clinical strategy for treating multiple myeloma.
Related Concept Videos
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
Abnormal Proliferation

